<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05006443</url>
  </required_header>
  <id_info>
    <org_study_id>21-003928</org_study_id>
    <nct_id>NCT05006443</nct_id>
  </id_info>
  <brief_title>Staging Classification of Severe Tricuspid Regurgitation Using Novel Cardiac Imaging Techniques</brief_title>
  <official_title>Staging Classification of Severe Tricuspid Regurgitation Using Novel Cardiac Imaging Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to assess the severity of tricuspid regurgitation (a disorder&#xD;
      in which the tricuspid valve in the heart does not close tight enough) using cardiac magnetic&#xD;
      resonance imaging (MRI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      40 patients with moderate or more TR on echocardiography will undergo CMR/MRE with contrast&#xD;
      to assess TR severity, and the associated extra-valvular cardiac and liver abnormalities as&#xD;
      shown in the flow diagram below. Patients will continue their clinical management by their&#xD;
      primary physicians as per the standards of care. 1-year follow up will be conducted via phone&#xD;
      to inquire about patient's vital status (dead/alive), symptoms and hospitalizations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Severity of tricuspid regurgitation by cardiac magnetic resonance imaging</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of severity of TR by CMR as compared with current gold standard (TTE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between severity of Tricuspid regurgitation by cardiac magnetic resonance imaging vs. elastography</measure>
    <time_frame>1 year</time_frame>
    <description>Correlation between severity of TR by CMR vs. echocardiography with 1-year composite endpoint of death, heart failure hospitalization, or tricuspid valve surgery.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>Moderate or severe tricuspid regurgitation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>40 patients with moderate or more TR on echocardiography will undergo CMR/MRE with contrast to assess TR severity, and the associated extra-valvular cardiac and liver abnormalities. Patients will continue their clinical management by their primary physicians as per the standards of care. 1-year follow up will be conducted via phone to inquire about patient's vital status (dead/alive), symptoms and hospitalizations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac Magnetic Resonance</intervention_name>
    <description>a non-invasive assessment to determine severity of tricuspid regurgitation</description>
    <arm_group_label>Moderate or severe tricuspid regurgitation</arm_group_label>
    <other_name>Cardiac MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate or more tricuspid regurgitation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior tricuspid valve prosthesis&#xD;
&#xD;
          2. Pacemaker/defibrillator that would impede MRI imaging&#xD;
&#xD;
          3. Planned tricuspid valve surgery&#xD;
&#xD;
          4. Primary liver pathology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamad Alkhouli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monica L Olson, MBA</last_name>
    <phone>507-255-2649</phone>
    <email>olson.monica2@mayo.edu</email>
  </overall_contact>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 31, 2021</study_first_submitted>
  <study_first_submitted_qc>August 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Mohamad Adnan Alkhouli</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

